why choose us

300×250 Ad Slot

Drug FDA Status

Showing 20 of 161 result(s) (Page 2 of 17)
Drug Name: Adquey

Active Ingredient: difamilast

Approval Date: 2026-02-12

Description: To treat mild to moderate atopic dermatitis

Drug Name: Zycubo

Active Ingredient: copper histidinate

Approval Date: 2026-01-12

Description: To treat Menkes disease

Drug Name: Myqorzo

Active Ingredient: aficamten

Approval Date: 2025-12-19

Description: To treat symptomatic obstructive hypertrophic cardiomyopathy

Drug Name: Exdensur

Active Ingredient: depemokimab-ulaa

Approval Date: 2025-12-16

Description: To treat severe asthma characterized by an eosinophilic phenotype as an add-on maintenance therapy

Drug Name: Lerochol

Active Ingredient: lerodalcibep-liga

Approval Date: 2025-12-12

Description: To reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise

Drug Name: Nuzolvence

Active Ingredient: zoliflodacin

Approval Date: 2025-12-12

Description: To treat uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae

Drug Name: Cardamyst

Active Ingredient: etripamil

Approval Date: 2025-12-12

Description: To treat episodes of paroxysmal supraventricular tachycardia

Drug Name: Voyxact

Active Ingredient: sibeprenlimab-szsi

Approval Date: 2025-11-25

Description: To reduce proteinuria in primary immunoglobulin A nephropathy in adults at risk for disease progression

Drug Name: Hyrnuo

Active Ingredient: sevabertinib

Approval Date: 2025-11-19

Description: To treat locally advanced or metastatic non-squamous non-small cell lung cancer with tumors that have activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy

Drug Name: Redemplo

Active Ingredient: plozasiran

Approval Date: 2025-11-18

Description: To reduce triglycerides in adults with familial chylomicronemia syndrome

300×250 Ad Slot